Pentigetide

Summary

Pentigetide is a synthetic IgE‑derived pentapeptide investigated for allergic eye and nasal inflammation. Clinical trials evaluated a 0.5% ophthalmic solution for allergic conjunctivitis and a nasal solution (1 mg per nostril four times daily) for seasonal allergic rhinitis. Both studies reported statistically significant symptom relief compared with active or placebo controls, and noted a favorable safety profile. The compound is classified as a research‑only agent and is no longer marketed.

Mechanism of Action

The exact pharmacologic mechanism of pentigetide has not been detailed in the published trials. As a synthetic peptide derived from the constant region of IgE, it is presumed to interact with pathways involved in IgE‑mediated allergic responses, potentially modulating mast cell activation or downstream inflammatory mediators. However, the cited studies focus on clinical outcomes rather than mechanistic investigations, and the precise target(s) remain unspecified in the literature.

What the Research Shows

Two double‑blind, randomized trials form the published evidence base for pentigetide. In 1991, a 15‑day study of 50 patients with allergic conjunctivitis compared 0.5% pentigetide eye drops to 4% cromolyn sodium. Physicians and patients rated the pentigetide group as significantly more improved on multiple ocular signs (hyperemia, edema, lacrimation, photophobia) and symptoms, with a 64% reduction in overall severity versus 46% for cromolyn. A separate multicenter trial enrolled 431 participants with seasonal allergic rhinitis, randomising them to pentigetide nasal solution (1 mg per nostril four times daily) or placebo for two weeks. Pentigetide produced statistically greater reductions in total nasal symptom scores and individual symptoms (sneezing, congestion, rhinorrhea), with consistent daily diary improvements. Both studies reported comparable adverse event rates between treatment and control groups.

Reported Benefits

Evidence from the conjunctivitis trial suggests pentigetide eye drops can more rapidly and markedly improve ocular redness, swelling, tearing, and visual discomfort than cromolyn sodium, achieving a greater overall symptom reduction. In allergic rhinitis, the nasal formulation demonstrated significant decreases in both frequency and severity of nasal symptoms compared with placebo, with patients and physicians reporting higher global improvement rates. Across both indications, the safety profile appeared similar to controls, with no serious ocular or systemic effects reported.

Limitations of the Evidence

The clinical data are limited to two short‑term trials conducted in the early 1990s, involving a total of 481 participants. Neither study examined long‑term efficacy or safety, and follow‑up beyond two weeks was not reported. Only two formulations (ophthalmic and nasal) were tested, leaving efficacy in other allergic conditions unaddressed. Comparative data are restricted to cromolyn sodium for eye disease and placebo for rhinitis; head‑to‑head comparisons with newer antihistamines or intranasal steroids are absent. Finally, the compound has been withdrawn from the market, limiting current availability for further research.

Safety Considerations

Both trials described adverse experiences as minor and comparable to control groups. In the ocular study, no clinically abnormal changes were observed in visual acuity, intra‑ocular pressure, or routine laboratory tests. The rhinitis trial reported no sedation, fatigue, or significant laboratory or vital‑sign alterations. Overall, pentigetide appeared well tolerated in the short term, but the limited duration and sample size preclude definitive conclusions about rare or long‑term adverse effects.

How It Is Administered

Pentigetide has been formulated as a 0.5% ophthalmic solution for topical eye administration and as a nasal solution delivering 1 mg per nostril four times daily. Both preparations are aqueous solutions intended for direct application to the affected mucosal surface. No other routes or dosage forms have been reported in the cited literature.

Routes of Administration

Goals & Uses

• Allergic rhinitis symptom reductionAllergy / ImmunologyLow
• Mast cell stabilizationAnti InflammatoryLow
• IgE-mediated allergy suppressionImmunomodulationLow

Contraindications

• Hypersensitivity to pentigetide or peptide componentsAllergyHigh

Adverse Effects

• Nasal irritationLocal/NasalCommon
• SneezingLocal ReactionCommon
• HeadacheNeurologicUncommonPain in the head or upper neck

Drug Interactions

• AntihistaminesLow

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo EMA marketing authorization granted. Not commercially available.
• United StatesUnapprovedInvestigated in clinical trials; FDA approval never obtained. Development discontinued.

Pentigetide was investigated in the US and other jurisdictions but was never approved by the FDA or EMA. Development was halted after Phase II/III trials failed to demonstrate adequate clinical benefit.

Evidence & Sources

• Double-blind trial of pentigetide ophthalmic solution, 0.5%, compared with cromolyn sodium, 4%, ophthalmic solution for allergic conjunctivitis
  Journal ArticleModerateKalpaxis JG, Thayer TO1991-01-01T00:00:00.000000Z
• Pentigetide nasal solution: a multicenter study evaluating efficacy and safety in patients with seasonal allergic rhinitis
  Journal ArticleModerateMansmann HC Jr, et al.1991-01-01T00:00:00.000000Z

Frequently Asked Questions